Myotonic dystrophy type 1 (DM1) is a debilitating multisystemic disorder caused by a CTG repeat expansion in the DMPK gene. Aberrant splicing of several genes has been reported to contribute to some symptoms of DM1, but the cause of muscle weakness in DM1 and elevated Ca 2+ concentrations in cultured DM muscle cells is unknown. Here we investigated the alternative splicing of mRNAs of two major proteins of the sarcoplasmic reticulum, the ryanodine receptor 1 (RyR1) and sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase (SERCA) 1 or 2. The fetal variants, ASI(-) of RyR1 which lacks residue 3481-3485, and SERCA1b which differs at the carboxyl-terminus, were significantly increased in skeletal muscles from DM1 patients and the transgenic mouse model of
INTRODUCTION
Myotonic dystrophy type 1 (DM1), the most common type of muscular dystrophy in adults, is a dominantly inherited multisystemic disorder caused by unstable expansion of CTG trinucleotide repeats in the myotonic dystrophy protein kinase (DMPK) gene (1) . The normal allele is polymorphic, ranging from 5 to 35 CTG repeats, whereas in DM1 the pathologic allele expands to between 50 and multiple thousands of CTG repeats. The clinical expression of DM1 includes myotonia, progressive muscle weakness, cataracts, insulin resistance and cardiac conduction defects .
Subsequently, myotonic dystrophy type 2 has been demonstrated to be caused by a CCTG repeat expansion located in intron 1 of the zinc finger protein 9 gene (2) .
In DM, disrupted mRNA splicing has been reported in several genes. These include cardiac troponin T (cTNT), insulin receptor (IR), muscle-specific chloride channel (ClC-1) and myotubularin-related protein 1 (MTMR1) (3) (4) (5) (6) in skeletal muscle and microtubule-associated tau, NMDA receptor 1 and amyloid precursor protein in the brain (7, 8) . In all cases, the developmental regulation of splicing is disrupted, resulting in preferential expression of fetal isoforms of the proteins.
In addition, we previously showed significant induction of mRNA for a small-conductance 5 IR-A, which is usually expressed in immature myotubes and other tissues with low insulin sensitivity (4) . In order to investigate a possible common mechanism of aberrant splicing, we compared the extent of abnormal splicing of ryanodine receptors with that of insulin receptors (Fig.2B) . The result showed significant correlation between the degree of abnormal splicing in RyR1 and that of the insulin receptor (Pearson correlation coefficient R=0.694, P=0.0374), suggesting that a common mechanism might contribute to the splicing abnormalities.
Another variant, ASII(-), which lacks ASII (exon 83, residues 3865-3870), is transiently expressed in skeletal muscle after birth and constitutes about 10% of RyR1 in adults. According to the previous study using mice, the splicing change in ASII (at around postnatal day (P) 8) takes place earlier than that in ASI (around P16) (14). We found that ASII(+) was dominantly expressed even in human myotubes (Fig. 2C) . Therefore, it is likely that the transition of ASII splicing pattern from ASII(-) to ASII(+) in human also takes place earlier than that of ASI. We did not find any change in ASII (-) expression in muscle among these groups of humans nor between HSA LR and WT mice (Fig. 2C ).
These results indicate that the ASII splice switch which occurs during a more developmentally immature state is not affected in DM1.
Splicing of SERCA1 isoforms
The mammalian SERCA1 has two major splice variants; SERCA1a (adult form) and SERCA1b
(neonatal form) (Fig. 1) . The difference between these isoforms results from the alternative splicing of exon 22, and consequently affects 7 amino acids located at the C-terminus. Recently, Chami described another splice variant (S1T), characterized by exon 4 and/or exon 11 skipping (20). S1T
transcripts were expressed in several tissues such as liver, lung and pancreas, but not in muscle.
Because exon 11 skipping leads to frame shift which results in premature stop codon in exon 12, S1T transcripts do not encode functional pumps.
We used a set of primers that co-amplify SERCA1 cDNAs with or without exon4, exon 11 and exon 22 splicing. SERCA1b (-exon 22) was exclusively expressed with other minor alternatively spliced variants in several DM1 muscles, whereas only SERCA1a (+ exon 22) was found in non-DM muscles (Fig. 3A) . The proportion of SERCA1b was significantly higher in DM1 muscles than in control (P=0.005), ALS (P=0.002) and PM (P=0.01). Moreover, the relative amount of SERCA1b was higher in myotubes from DM1 patients compared with those from normal control (Fig. 3A) . On the other hand, the S1T isoform was not detected in either DM1 or non-DM muscle (data not shown).
We then analyzed SERCA1 variants in skeletal muscles and myotubes in HSA LR mice. As with DM1
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It has been reported that the mammalian SERCA2 has three splice variants; SERCA2a, SERCA2b
and SERCA2c that differ in their C-terminal region as is the case in SERCA1 isoforms (Fig.1 ).
Although SERCA1 splicing is developmentally regulated, splicing of SERCA2 is regulated in a tissue specific manner. SERCA2a is the major isoform in cardiac muscle and type 1 skeletal muscle.
SERCA2b is expressed in smooth muscle and many other tissues as a house-keeping gene, although it has three mRNA subclasses which differ only in their 3'-untranslated region and are regulated in a and its flanking exons has been found in the EST database (sequence number BG011840).
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(25) and another showed increase in SERCA1 expression in DM skeletal muscles (26) . We found a trend toward increased levels of SERCA1 and SERCA2 proteins in the SR fraction of HSA LR muscle, but not of RyR1 (n=2, Fig. 6 ). Clearly, SERCA1 protein levels were not decreased, suggesting that functional differences caused by aberrant splicing of RyR1, SERCA1, and SERCA2 alone may contribute to Ca 2+ dysregulation in DM.
Functional studies of ASI(+) and ASI(-)
In order to examine the functional difference between the ASI(+) and ASI(-) RyR1 isoforms, we (29) . In addition, compared to normal myotubes, ASI(+)-expressing dyspedic myotubes exhibit an increased tendency for Ca 2+ oscillations during application of 10 mM caffeine (76% in the study of (30)). Since the ASI(-) isoform is uniformly expressed in developmentally immature normal myotubes (see Fig. 2A ), these results could reflect inherent differences in ASI(+) and ASI(-). Therefore, we characterized caffeine-induced Ca 2+ release in ASI(+)-and ASI(-)-expressing dyspedic myotubes (Fig. 8 ). For these experiments, ASI(+) and ASI(-) were cloned into pCIneo and injected at the same concentration (0.5 µg/µl) in myotubes derived from RyR1-knockout (dyspedic) mice. In addition, other nuclear RNA binding proteins could be sequestrated in RNA foci, because nuclear mRNAs exist as multimeric ribonucleoprotein (RNP) complexes rather than naked polynucleotides (8).
However, Jiang reported that the overall distribution of hnRNP H or F did not show obvious changes in DM (8). Accordingly, we did not find any splicing abnormality of β-tropomyosin (data not shown), which is developmentally regulated via proteins including hnRNP H, I and A1 (34), suggesting that alterations in these RNP proteins are not directly related to aberrant splicing in DM. release channels that are excessively leaky to Ca 2+ and thus result in a depleted Ca 2+ reservoir available for release during muscle activation. Alternatively, the "EC-uncoupling hypothesis"
Mutations of
proposes that CCD mutations in the pore region of RyR1 result in a deficit in EC coupling, i.e. reduced Ca 2+ release in the presence of normal SR Ca 2+ content (35, 37). In theory, aberrant splicing of RyR1 could contribute to muscle weakness in DM via either of these two mechanisms. However, it is unlikely that the ASI(-) variant results in significant SR Ca 2+ leak since maximal caffeine-induced Ca 2+ release is identical in ASI(+) and ASI(-) expressing dyspedic myotubes (Fig. 8) . In addition, the leaky channel mutants exhibit impaired Ca 2+ inhibition by high Ca 2+ (35), while the Ca 2+ dependence of inactivation is similar for ASI(-) and wt-RyR1 (Fig. 7D) We identified a novel splice variant of SERCA2 (SERCA2d) in skeletal muscle and found that the proportion of SERCA2d was reduced in DM1. SERCA2d contains intron 19 and its retention leads to a frameshift encoding 27 amino acids (VSGWVGLGTSHLLPGEAGGVTRLPCVS) in the C-terminus that is followed by a premature stop codon in exon 20. Several studies have suggested that the C-terminal region of SERCA2 is a critical determinant of its functional properties. The SERCA2a and SERCA2b splice variants also differ in their C-terminus. SERCA2b exhibits a two-fold higher apparent affinity for Ca 2+ , but at the same time a two-fold lower catalytic turnover rate (18, 42, 43 proteins including the fetal isoform of myosin heavy chain and cardiac troponin are not increased in DM1 muscle fibers (4), the interaction between these two juvenile variants and adult isoforms of other skeletal muscle proteins may also be disturbed.
Although HSA LR mice exhibit a consistent muscle histopathology, with increases in central nuclei and ring fibers and variability in fiber size, severe muscle weakness is not observed in these animals up to the age of 6 months (19) . This illustrates that these splicing differences cannot themselves explain muscle wasting. However, the possibility that the mice might exhibit muscle wasting with aging or hormonal changes was not excluded because older mice were not examined. Thus, the development of severe muscle weakness may require other factors such as aging, hormonal changes, or other yet to be identified splicing abnormalities. In fact, younger DM1 patients often exhibit a similar muscle histology in the absence of weakness and severe degeneration/regeneration which can develop later (45).
In conclusion, our work characterizes aberrant splicing of RyR1, SERCA1, and SERCA2 in DM1. 
MATERIALS AND METHODS

RNA preparation and cDNA synthesis
Human muscle tissues were obtained from 26 biopsy specimens; 10 from DM1, 6 from normal control, 5 from ALS, and 5 from PM. All muscle specimens were frozen immediately after biopsy in a dry ice isopentane bath and stored at −80°C until analysis. Myotubes were cultured from 2 muscle specimens; 1 from DM1 and 1 from normal control. Primary myoblast cultures were established as described previously (46). The differentiation to myotubes was induced by reducing the concentration of fetal bovine serum to 5 %. Informed consent for use of specimens for research purposes was obtained from each patient with the approval of institutional ethical committee. We also employed skeletal muscle of hind limb from 5 HSA LR and 4 WT mice. The experiments using mice were performed in accordance with the protocol complying with the Guideline for the Care and Use of Laboratory Animal at the Osaka University Graduate School of Medicine. Total mRNA was extracted from each sample by ISOGEN procedure (Nippon Gene, Japan). First-strand cDNA was synthesized using 1-3 µg of total mRNA, 1 µM random hexamer RT primer, 0.5 mM dNTPs and 600 U reverse transcriptase at 42°C for 1 h. cDNA equivalent to 20 ng of total mRNA was used for PCR in the final volume of 20 µl.
PCR analysis of splicing pattern
The sequences of primers used for RT-PCR assays of splicing in human muscle RNA are listed in supplementary data Table 1 . PCR was repeated 30 cycles for human SERCA2a, 32 cycles for human SERCA1, and 35 cycles for the others. Assays reflect the proportion of splicing isoforms with annealing temperatures of 62 for SERCA1, 55 for SERCA2a/b and 60 for the rest.
Quantitative RT-PCR study
The primers designed for semi-quantitive RT-PCR study of RyR1, RyR3, SERCA1, and SERCA2 of human are listed in supplementary data Table 2 . Two primer sets for human and mouse glyceraldehyde-3-phosphate dehydrogenase (G3PDH) (Clontech, Palo Alto, USA) were used as an internal control. PCR was repeated 32 cycles for human SERCA 1,2a/b, 28 cycles for human G3PDH, and 30 cycles for the others within the range of exponential amplification, with annealing temperatures of 62 for SERCA1, 2a/b and 60 for the others.
The PCR product for both studies was electrophoresed on 8 % polyacrylamide gels for separation.
Quantitative analysis of the amplified products was performed by Fluorimager595 (Amersham Biosciences, Buckinghamshire, UK). The quality of PCR products was ascertained by sequencing representative samples. Sequencing was performed using a dye deoxy terminator cycle sequencing kit and a DNA sequencer (373A; Applied Biosystems, Foster, USA).
13 site-directed mutagenesis strategy and the entire PCR-modified cDNA portion of the clone was ultimately confirmed by sequence analysis. HEK293T cells were grown in 100 mm petri dishes at 37°C, 5 % CO 2 in MEM complemented by 10 % fetal calf serum. At 50-60 % confluency, cells were transfected with a mammalian expression vector (pCIneo) encoding either ASI(+) or ASI(-) (40 µg DNA per plate) using calcium phosphate precipitation method. Cells maintained for 48h were collected in harvest buffer (137 mM NaCl, 3 mM KCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , 0.5 mM EDTA, (pH 7.4 with NaOH)) and centrifuged for 10 min at 100 g. The pellet was resuspended in ice-cold hypotonic buffer (1 mM EDTA, 1 µg/ml leupeptin, 500 µM phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin A, 1 µg/ml aprotinin, 1 mM benzamidine, 10 mM HEPES pH 7.4), homogenized on ice, added with equal volume of ice-cold 20 % sucrose buffer (10 mM HEPES, pH 7.4), and centrifuged at 110,000 g for 45 min at 4°C. The pellet was then resuspended in 1 ml of buffer containing 10 % sucrose and 10 mM HEPES (pH 7.4) and stored under liquid nitrogen until use. Non-specific binding was measured in the presence of 667-fold molar excess of cold ryanodine.
Binding assay was filtered through Whatmann GF/F filters, which were then washed three times with 3 ml of ice-cold solution containing 100 mM KCl, 20 mM PIPES pH 6.8, 1 mM EGTA, and the indicated free Ca
2+
. Radioactivity bound to the filters was measured by scintillation counting.
Isolation and reconstitution of expressed RyR
The ryanodine receptor was isolated as described by Lee et al. Threshold levels for channel opening and closing were set to exclude baseline noise at ~20 % of the maximum single channel conductance.
Preparation and cDNA injections of dyspedic myotubes
Primary cultures of dyspedic myotubes were generated from skeletal muscle myoblasts obtained from neonatal dyspedic mice as previously described (50). 5-7 days after initial plating, individual myotube nuclei were microinjected with pCIneo encoding either ASI(+) or ASI(-) (0.5 µg/µl).
Coinjection of CD8 cDNA (0.1 µg/µl) was used to enable identification of expressing myotubes via incubation with antiCD8 antibody-coated beads. Experiments were carried out on the third day following microinjection. 
Measurements of resting Ca
